Jamilet Miranda

Employment

• Center for Genetic Engineering and Biotechnology (CIGB) MSc. in Mathematics

Education

• University of Havana
• TU Dresden

Projects & Funding

Projects & funding information is unavailable.

Publications (17)

• Integrated Analysis of HeberFERON-Driven Comparative Proteomic regulation in Glioblastoma Cells U-87MG
  2026 DOI: 10.64898/2026.04.22.720155
  +Save
• Regulation of Extracellular HMGB-1 Alarmin Levels by CIGB-300 Anticancer Peptide In Vitro and In Vivo
  Kinases and Phosphatases 2026 DOI: 10.3390/kinasesphosphatases4030020
  +Save
• A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG
  BMC Cancer 2023 DOI: 10.1186/s12885-023-11330-2
  +Save
• HeberFERON distinctively targets Cell Cycle in the glioblastoma-derived cell line U-87MG
  2022 DOI: 10.1101/2022.09.22.508971
  +Save
• Biomarkers of sequela in adult patients convalescing from COVID-19
  Advances in Biomarker Sciences and Technology 2022 DOI: 10.1016/j.abst.2022.10.001
  +Save
• Targeting CK2 mediated signaling to impair/tackle SARS-CoV-2 infection: a computational biology approach
  Molecular Medicine 2021 DOI: 10.1186/s10020-021-00424-x
  +Save
• CIGB-300 Synthetic Peptide, an Antagonist of CK2 Kinase Activity, as a Treatment for Covid-19. A Computational Biology Approach
  2021 DOI: 10.21203/rs.3.rs-795492/v1
  +Save
• CIGB-300 synthetic peptide, an antagonist of CK2 kinase activity, as a treatment for Covid-19. A computational biology approach
  2021 DOI: 10.1101/2021.07.26.453805
  +Save
• Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy
  Journal of Translational Medicine 2020 DOI: 10.1186/s12967-020-02613-4
  +Save
• Gene expression profile in cervical carcinoma cells treated with HeberFERON
  Bionatura 2018 DOI: 10.21931/rb/2018.03.04.3
  +Save